Sarpatwari A - Search Results

1

Removing ERISA's Impediment to State Health Reform.

Fuse Brown EC, Sarpatwari A. Fuse Brown EC, et al. Among authors: sarpatwari a. N Engl J Med. 2018 Jan 4;378(1):5-7. doi: 10.1056/nejmp1709167. N Engl J Med. 2018. PMID: 29298152 No abstract available.

2

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product.

Luo J, Kesselheim AS, Sarpatwari A. Luo J, et al. Among authors: sarpatwari a. Lancet Diabetes Endocrinol. 2020 May;8(5):360-362. doi: 10.1016/S2213-8587(20)30105-4. Epub 2020 Mar 20. Lancet Diabetes Endocrinol. 2020. PMID: 32203681 Free PMC article. No abstract available.

3

Using a drug-safety tool to prevent competition.

Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488. N Engl J Med. 2014. PMID: 24738666 No abstract available.

4

Ensuring patient privacy in data sharing for postapproval research.

Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Sarpatwari A, et al. N Engl J Med. 2014 Oct 23;371(17):1644-9. doi: 10.1056/NEJMsb1405487. N Engl J Med. 2014. PMID: 25337755 No abstract available.

5

Practical, legal, and ethical issues in expanded access to investigational drugs.

Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Darrow JJ, et al. Among authors: sarpatwari a. N Engl J Med. 2015 Jan 15;372(3):279-86. doi: 10.1056/NEJMhle1409465. N Engl J Med. 2015. PMID: 25587952 No abstract available.

6

Paying physicians to prescribe generic drugs and follow-on biologics in the United States.

Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2015 Mar 17;12(3):e1001802. doi: 10.1371/journal.pmed.1001802. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25781468 Free PMC article.

7

Expanded access to investigational drugs.

Sarpatwari A, Darrow JJ, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2015 Apr 9;372(15):1473-4. doi: 10.1056/NEJMc1501823. N Engl J Med. 2015. PMID: 25853762 No abstract available.

8

Progress and Hurdles for Follow-on Biologics.

Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6. N Engl J Med. 2015. PMID: 25946143 No abstract available.

9

Forbidden and Permitted Statements about Medications--Loosening the Rules.

Avorn J, Sarpatwari A, Kesselheim AS. Avorn J, et al. Among authors: sarpatwari a. N Engl J Med. 2015 Sep 3;373(10):967-73. doi: 10.1056/NEJMhle1506365. N Engl J Med. 2015. PMID: 26332553 No abstract available.

10

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

Sarpatwari A, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb. PLoS Med. 2016. PMID: 26859662 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results